Table 2.
Overview of relevant large scale registries forchronic heart failure care programmes in European countries
| Registry of chronic HF patients | Cohort size* | Inclusion period | Publication date | Mean age | Gender, female | Ischaemic aetiology | Comorbidity, HT vs DM % | Medication ACE/ARB; BB; MRA |
ICD/CRT-D therapy, % |
|---|---|---|---|---|---|---|---|---|---|
| EuroHeartFailure survey [6] | 11,304 | 2001–2003 | 2003 | 71 | 47 | 39 | n/a vs 20% | 62%; 37%; 21% | n/a |
| ESC-HF Pilot study (n = 5118) [7] | 3226 | 2009–2010 | 2010 | 67 | 30 | 50 | 58% vs 29% | 88%; 87%; 44% | ICD 13%, CRT-D 9% |
| ESC-HF-Long-term-Registry [8, 9] | 7401 | 2011–2013 | 2013 | 66 | 29 | 43 | 58% vs 32% | 89%; 89%; 59% | n/a |
| The Swedish Heart Failure Registry (S-HFR), subset with EF < 30% [12] | 5908 | 2003–2012 | 2016 | 72 | 23 | 61 | 34–48% vs 70% | 88%; 85%; 53% | 4–10% |
| Evidence-based Treatment in HF registry (Germany): EVITA-HF [13] | 1853 | 2004–2011 | 2014 | 70 | 24 | 56 | 76% vs 39% | 73%; 71%; 32% | 18% |
| Spanish National Registry on Heart Failure: the RICA registry [14] | 1368 | 2008–2013 | 2015 | 78 | 53 | n.a. | 86% vs 47% | 87%; 64%; 32% | n/a |
| Italian Network on Heart Failure Outcome registry IN-HF (n = 5610) [15] | 3755 | 2007–2009 | 2013 | 69 | 24 | 46 | 43% vs 30% | Not specified | ICD 19%, CRT-D 7% |
| Adherence to guidelines in chronic HF: the MAHLER survey [16] | 1410 | 2001–2002 | 2005 | 69 | 31 | 68 | n/a | 69%; 53%; 28% | n/a |
| Data from the GWTG-HF (Get With The Guidelines) registry [17] | 10,148 | 2005–2007 | 2009 | 68 | 36 | 15* | n/a | n/a | 20% |
| The QUALIFY international registry [19] | 6669 | 2013–2014 | 2017 | 63 | 26 | n/a | 64% vs 34% | 87%; 87%; 69% | ICD 12.1%, CRT-D 7.2% |
*cohort size related to chronic heart failure with reported medication use
ACE enzyme inhibitor, ARB angiotensin II receptor blocker, BB beta-blocker, DM diabetes mellitus, HF heart failure, HT hypertension, ICD implantable cardioverter defibrillator, CRT-D cardiac resynchronisation therapy defibrillator, MRA mineralocorticoid receptor antagonist, n/a not available